BACKGROUND: Left ventricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by the formation of anti-human leukocyte antigen antibodies. Whether sensitization occurs with continuous axial flow LVAD implant as assessed by single antigen bead (SAB) assay is unknown. METHODS: Cytotoxic panel-reactive antibody (PRA) and SAB assays were analyzed in HTX recipients undergoing LVAD implant as a BTT. Sensitization was defined as peak anti-human leukocyte antigen antibody values of more than 2000 mean fluorescence intensity because these values have been found to correlate with flow cytometric crossmatch results. RESULTS: LVADs were implanted as BTT in 30 patients. There were 7% (2 of 30) of patients before LVAD implant and no patients after LVAD implant with PRA more than 10%. However, 20% (6 of 30) of patients before LVAD and 53% (16 of 30) after LVAD were sensitized as measured by SAB (P=0.024). At HTX, 47% (14 of 30) of patients remained sensitized. A positive virtual crossmatch was observed in 28% (4 of 14) of the sensitized patients at HTX. There was no difference between the sensitized and nonsensitized groups (P>0.4 for all) in usage of blood products (6411 vs. 6339 units) and time to HTX (28,663 vs. 25,748 days), and 1 year after HTX, there were no differences in rejection (total rejection score 0.30 vs. 0.37) and survival (93% vs. 88%). CONCLUSION: Allosensitization after LVAD is common despite cytotoxic PRA being negative. One year after HTX, this sensitization does not translate into increased acute cellular or antibody-mediated rejection or reduced survival.
BACKGROUND: Left ventricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by the formation of anti-human leukocyte antigen antibodies. Whether sensitization occurs with continuous axial flow LVAD implant as assessed by single antigen bead (SAB) assay is unknown. METHODS:Cytotoxic panel-reactive antibody (PRA) and SAB assays were analyzed in HTX recipients undergoing LVAD implant as a BTT. Sensitization was defined as peak anti-human leukocyte antigen antibody values of more than 2000 mean fluorescence intensity because these values have been found to correlate with flow cytometric crossmatch results. RESULTS: LVADs were implanted as BTT in 30 patients. There were 7% (2 of 30) of patients before LVAD implant and no patients after LVAD implant with PRA more than 10%. However, 20% (6 of 30) of patients before LVAD and 53% (16 of 30) after LVAD were sensitized as measured by SAB (P=0.024). At HTX, 47% (14 of 30) of patients remained sensitized. A positive virtual crossmatch was observed in 28% (4 of 14) of the sensitized patients at HTX. There was no difference between the sensitized and nonsensitized groups (P>0.4 for all) in usage of blood products (6411 vs. 6339 units) and time to HTX (28,663 vs. 25,748 days), and 1 year after HTX, there were no differences in rejection (total rejection score 0.30 vs. 0.37) and survival (93% vs. 88%). CONCLUSION: Allosensitization after LVAD is common despite cytotoxic PRA being negative. One year after HTX, this sensitization does not translate into increased acute cellular or antibody-mediated rejection or reduced survival.
Authors: David L Joyce; Robert E Southard; Guillermo Torre-Amione; George P Noon; Geoffrey A Land; Matthias Loebe Journal: J Heart Lung Transplant Date: 2005-09-15 Impact factor: 10.247
Authors: E S Bishay; D J Cook; R C Starling; N B Ratliff; J White; E H Blackstone; N G Smedira; P M McCarthy Journal: Eur J Cardiothorac Surg Date: 2000-04 Impact factor: 4.191
Authors: M G Massad; P M McCarthy; N G Smedira; D J Cook; N B Ratliff; M Goormastic; R L Vargo; J Navia; J B Young; R W Stewart Journal: J Thorac Cardiovasc Surg Date: 1996-11 Impact factor: 5.209
Authors: M J Gandhi; S R DeGoey; K Bundy; W K Kremers; R Knauer; N Pereira; B Edwards; S Kushwaha; R C Daly Journal: Transplant Proc Date: 2011-12 Impact factor: 1.066
Authors: Lois U Nwakanma; Jason A Williams; Eric S Weiss; Stuart D Russell; William A Baumgartner; John V Conte Journal: Ann Thorac Surg Date: 2007-11 Impact factor: 4.330
Authors: James M Gloor; Steven DeGoey; Nancy Ploeger; Howard Gebel; Robert Bray; S Breanndan Moore; Patrick G Dean; Mark D Stegall Journal: Transplantation Date: 2004-07-27 Impact factor: 4.939
Authors: Isaac George; Patrick Colley; Mark J Russo; Timothy P Martens; Elizabeth Burke; Mehmet C Oz; Mario C Deng; Donna M Mancini; Yoshifumi Naka Journal: J Thorac Cardiovasc Surg Date: 2008-06 Impact factor: 5.209
Authors: Peter Chiu; Justin M Schaffer; Philip E Oyer; Michael Pham; Dipanjan Banerjee; Y Joseph Woo; Richard Ha Journal: J Heart Lung Transplant Date: 2016-01-07 Impact factor: 10.247
Authors: Ahmet Kilic; Sitaramesh Emani; Chittoor B Sai-Sudhakar; Robert S D Higgins; Bryan A Whitson Journal: J Thorac Dis Date: 2014-08 Impact factor: 2.895
Authors: Murray H Kwon; Jennifer Q Zhang; Joanna M Schaenman; Martin Cadeiras; David W Gjertson; Carolyn A Krystal; Hillel Laks; Abbas Ardehali; Mario C Deng; Richard J Shemin; Elaine F Reed Journal: J Thorac Cardiovasc Surg Date: 2015-01-08 Impact factor: 5.209
Authors: Sarah B See; Kevin J Clerkin; Peter J Kennel; Feifan Zhang; Matthew P Weber; Kortney J Rogers; Debanjana Chatterjee; Elena R Vasilescu; George Vlad; Yoshifumi Naka; Susan W Restaino; Maryjane A Farr; Veli K Topkara; Paolo C Colombo; Donna M Mancini; P Christian Schulze; Bruce Levin; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2017-03-24 Impact factor: 10.247